Revenio Group (REG1V) Fair Value & Analysis
Healthcare · FI · Market cap €365M
Fair value as of: Jul 19, 2026
From 26 valuation models · updated 22 days ago
Fair value updated Jul 19, 2026, revised from €14.39 to €13.16 (−8.5%) since Jul 18, 2026. Share price +7.5% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from €9.87 (bear) to €16.45 (bull), base €13.16. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 72/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.
How to read this chart
60‑month range €11.88 – €67.31 · fair‑value band €9.87 – €16.45 · the €13.42 price screens above the €13.16 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 19, 2026.
Analysis
Revenio Group (REG1V) currently trades at €13.42, while our model-based Fair Value estimate is €13.16, implying the stock looks roughly 1.9% fairly valued today. The Quality Score stands at 72/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Revenio Group generated revenue of €111M at a net margin of 14.2%. Revenue grew 4.6% year over year. It earns a return on equity of 13.7%. The balance sheet holds a net cash position of €15.2M. Fundamentals as of Jul 19, 2026
Our scenario range runs from €9.87 (bear case) to €16.45 (bull case); at €13.42, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 54% below its 52-week high and 1% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -2%, REG1V screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (€15.91) versus Asset-Based (€2.64). Highest evidence: Growth DCF (80).
Notify me when REG1V reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 73 · Market factors (momentum, volatility) 28
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally.
Full company description
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by veterinarians, ophthalmologists and other personnel to measure intraocular pressure in animal patients. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers iCare ILLUME, a screening software that helps to detect the early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma using artificial intelligence; iCare CLINIC cloud software to store long-term IOP data; and Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Revenio Group reported revenue of €110M in FY2025 versus €78.8M in FY2021, a compound +8.6%/yr. Reported net income was €17.4M in FY2025, compounding +0.1%/yr from FY2021.
of which total revenue +20.1 pp · buybacks/dilution −1.5 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch REG1V: get an alert when its fair value changes →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Revenio Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Revenio Group (REG1V) overvalued or undervalued?
What is the fair value of REG1V?
What is the quality score of REG1V?
What is the revenue of Revenio Group (REG1V)?
What is the net profit margin of REG1V?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Revenio Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.